TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01456481

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: midodrine hydrochloride
Description: Target dose is midodrine hydrochloride or placebo pills 10 mg three times a day for 12 months. The starting dose is 5mg q4h x3, and if tolerated a forced titration up to 10mg/dose. If there is an intolerance, then the dose can be reduced to 2.5mg/dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: midodrine hydrochloride
Description: Target dose is midodrine hydrochloride or placebo pills 10 mg three times a day for 12 months. The starting dose is 5mg q4h x3, and if tolerated a forced titration up to 10mg/dose. If there is an intolerance, then the dose can be reduced to 2.5mg/dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: matching placebo
Description: The target dose in this study is 10mg q4h x3 for 12 months. The starting dose is 5mg q4h x3, and if tolerated a forced titration up to 10mg/dose. If there is an intolerance, then the dose can be reduced to 2.5mg/dose.
Study: NCT02369042

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kyma Device u-Cor System
Description: The Kyma uCor system externally measures thoracic fluid content, heart rate, respiratory rate, posture and movement. The system includes a flat antenna that is attached to the patient's torso with a bandage-like sticker. The antenna transmits radio waves and receives their reflections from the body for several seconds every few hours throughout the day.The data is recorded and collected then compared to traditional clinical parameters.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kyma Device u-Cor System
Description: The Kyma uCor system externally measures thoracic fluid content, heart rate, respiratory rate, posture and movement. The system includes a flat antenna that is attached to the patient's torso with a bandage-like sticker. The antenna transmits radio waves and receives their reflections from the body for several seconds every few hours throughout the day.The data is recorded and collected then compared to traditional clinical parameters.
Study: NCT02531932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be administered if ANC \> 1.0 and platelets are \>75k

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin will be administered if ANC \> 1.0 and platelets are \>75k
Study: NCT03975985

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Physiotherapy
Description: The common feature of CP is that it consists of a management by the physiotherapist according to the CP may consist in a variety (or combination) of multiple components such as tone normalization, exercises for maintain range of motion, passive mobilization of hemiparetic side, postural control, gait re-education to walking/standing between parallel bars or with a therapist, rehabilitation of the activity of daily living, etc.
Study: NCT01391078

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sensimed Triggerfish Sensor
Description: IOP will be monitored for 24 hours

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Goldmann Applanation Tonometry, Perkins Tonometry
Description: IOP will be measured every two hours within 24 hours
Study: NCT02531932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: The study drug Everolimus will be self-administered (by the patients themselves).
Study: NCT01562496

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: six-months long exercise intervention on a stationary virtual reality bike, 3-5 times a week, each session lasting 30-45 minutes at a target heart rate (60-85% heart rate reserve).
Study: NCT02301247

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Memory retraining exercises
Description: Memory retraining exercises will be administered on a laptop computer twice a week for 5 weeks (10 training sessions).

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control memory exercises
Description: Placebo control memory exercises will be administered on a laptop computer twice a week for 5 weeks (10 training sessions).
Study: NCT03818048

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: after inicial bolus of propofol, remained sedated with propofol infusion (1-2 mg/kg/min)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: after inicial bolus of propofol, remained sedated by inhalation with sevoflurane at a concentration of 2 vol% through a nasal cannula with an oxygen flow.
Study: NCT01241968

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac Extracorporeal Shockwave Therapy generator (Cardiospec)
Description: Energy Density - 0.09 mJ/mm2

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02334904

Intervention type: DRUG
Intervention: Aripiprazole
Description: To be prescribed and monitored by participant's attending physician (not given to participants as a part of the study)

Intervention type: DRUG
Intervention: Risperidone
Description: To be prescribed and monitored by participant's attending physician (not given to participants as a part of the study).
Study: NCT00353483

Intervention type: PROCEDURE
Intervention: Peripheral blood draw

Intervention type: PROCEDURE
Intervention: Breast tissue collection

Intervention type: PROCEDURE
Intervention: Bone marrow biopsy
Study: NCT04871126

Intervention type: OTHER
Intervention: inflammatory indexes and CHA2DS2-VASc score
Description: inflammatory indexes and CHA2DS2-VASc score

Intervention type: OTHER
Intervention: inflammatory indexes and CHA2DS2-VASc score
Description: inflammatory indexes and CHA2DS2-VASc score
Study: NCT00843596

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cardiac surgery requiring ECC
Description: the vacuum device is left on the 2 wounds (caused by the ECC cannulas) for 15 min (possible a second time of 15 min : 30 min max.)
Study: NCT03742323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idelalisib
Description: Idelalisib Dose: 100, 150, 200 or 300 mg (in four cohorts of six patients each).
Study: NCT01136161

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RUTI
Description: dose:5 micrograms of FCMtb (Fragmented cells of M. tuberculosis); given subcutaneously twice, on days 28 and 56.
Study: NCT01505257

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: END-DSD
Description: Multi-component intervention including 1) Nursing education regarding detection and management of delirium superimposed on dementia; 2) Computerized decision support and EHR; 3) A unit champion nurse for promotion of delirium assessment and management; 4) Feedback to nursing staff
Study: NCT00796822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Description: 400 mg three times a day for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One pill three times a day for 8 weeks
Study: NCT01136161

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RUTI
Description: dose:5 micrograms of FCMtb (Fragmented cells of M. tuberculosis); given subcutaneously twice, on days 28 and 56.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RUTI
Description: dose:25 micrograms of FCMtb (Fragmented cells of M. tuberculosis); given subcutaneously twice, on days 28 and 56.
Study: NCT01398384

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitric Oxide
Description: MI size at 48-72 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MI size at 48-72 hours
Description: Placebo gas
Study: NCT03244774

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib 250mg p.o. qd in first cohort (3 subjects). 375mg p.o. qd in second cohort (3 subjects). 500mg p.o. qd in third cohort (3 subjects). 625mg p.o. qd in forth cohort (3 subjects); 750mg p.o. qd in fifth cohort (3 subjects).~Other Name:

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: POF
Description: The POF regimen consisted of a 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and Calcium Levofolinate (200 mg/m2).Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days.
Study: NCT00048646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Progesterone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IV Progesterone
Study: NCT01136161

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RUTI
Description: dose:25 micrograms of FCMtb (Fragmented cells of M. tuberculosis); given subcutaneously twice, on days 28 and 56.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RUTI
Description: dose:50 micrograms of FCMtb (Fragmented cells of M. tuberculosis); given subcutaneously twice, on days 28 and 56.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RUTI
Description: dose:50 micrograms of FCMtb (Fragmented cells of M. tuberculosis); given subcutaneously twice, on days 28 and 56.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: RUTI Matching Placebo
Description: Placebo of the vaccine RUTI; given subcutaneously twice, on days 28 and 56.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: RUTI Matching Placebo
Description: Placebo of the vaccine RUTI; given subcutaneously twice, on days 28 and 56.
Study: NCT03365089

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Collateral vein ligation
Description: Collateral venous flow will be interrupted by ultrasound-guided ligation of venous side branches.
Study: NCT02645669

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Study site
Description: The probiotic is in the form of a lyophilized powder containing approximately 5 billion colony forming units (CFU) of the Saccharomyces boulardii. At the time of administration, the probiotic mixture was mixed with fructooligosaccharide in the ratio of 4:1 to induce growth and activity in S boulardii. This was applied after scaling and root planing.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Control site
Description: Only Scaling and Root planing was done.
Study: NCT01878370

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High risk
Description: Aggregate-level feedback reports focusing on the proportion of patients with hypertension and/or diabetes and/or ischemic heart disease meeting criteria for high-risk sent via courier every six months and available on a password protected website. Family physicians in this arm will also have access through this website to a list of chart numbers identifying those patients at highest risk.~Family physicians in Arm 2 are asked to complete a worksheet that also includes goal setting and action planning, but focuses on reducing the number of patients with high-risk criteria and offers some suggested practice-based approaches.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Practice
Description: Standard, aggregate-level feedback reports focusing on the proportion of patients with hypertension and/or diabetes and/or ischemic heart disease meeting targets sent via courier every six months and available on a password protected website. Family physicians in this arm will also have access through this website to patient-level data to identify patients not achieving optimal quality of care targets.~Family physicians in Arm 1 are asked to complete a worksheet that follows continuous quality improvement principles, including setting an aim statement, engagement with team members in the clinic, testing change concepts at first on a small scale, and then scaling up in a effort to spread best practices.
Study: NCT02619799

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intrathecal magnesium sulphate,
Description: comparision of effects of intrathecal magnesium sulphate with intrathecal midazolam when administered along with epidural 0.75% Ropivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intrathecal midazolam
Description: comparision of effects of intrathecal magnesium sulphate with intrathecal midazolam when administered along with epidural 0.75% Ropivacaine
Study: NCT00638599

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LMA®
Description: LMA® is placed after anesthesia induction and removed after the operation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endotracheal tube
Description: Standard endotracheal tube is inserted after anesthesia induction and extubated after the operation
Study: NCT03363815

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-90001
Description: CC-90001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-90001
Description: CC-90001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-90001
Description: CC-90001
Study: NCT01357603

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Glargine
Description: dosage form: Subcutaneous injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Glargine
Description: dosage form: Subcutaneous injection
Study: NCT03799666

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary Rehabilitation
Description: Patients will be treated with daily medication prescribed by the physician. Additionally patients will participate in a 12-w.eek community-based pulmonary rehabilitation programme, with two exercise training sessions per week and six psycho-education sessions, managed by a multidisciplinary team, once every two weeks. Patient's families will be invited to participate in the psychoeducational component

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Daily medication
Description: Patients will be treated with daily medication prescribed by the physician and will continue to receive the standard care from the primary care centre team.
Study: NCT00920140

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1120212
Description: Starting dose based on GSK protocol MEK111054 and then dose escalation based on Dose Limiting Toxicities per protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1120212
Description: Dose will be maximum tolerated dose based on Phase I results.
Study: NCT00148915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibandronate
Study: NCT01764880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SST0001 (Roneparstat)
Description: SST0001 once daily for 5 or 10 days in a cycle of 28 days.
Study: NCT02027441

Intervention type: OTHER
Intervention: Standard Counseling and Testing
Description: Individuals who opt for standard counseling and testing will complete the following procedures:~• Standardized pre- and post-test counseling and HIV testing using HIV rapid test per approved national guidelines
Study: NCT00148915

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo
Study: NCT03577509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABCD
Description: Intravenous infusion of dexamethasone 5mg before ABCD intravenous administration; Single infusion.
Study: NCT00802802

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz (EFV)
Description: Participants will be administered oral EFV at a dose ranging from 50 mg to 800 mg once daily, based on weight and CYP 2B6 genotype. EFV capsules will be opened into a small amount of a compatible food or liquid vehicle; the smallest amount of food or liquid that will enable the child to swallow the capsule contents should be used (i.e., EFV should not be taken with a meal).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz (EFV)
Description: Participants will be administered oral EFV at a dose ranging from 50 mg to 800 mg once daily, based on weight and CYP 2B6 genotype. EFV capsules will be opened into a small amount of a compatible food or liquid vehicle; the smallest amount of food or liquid that will enable the child to swallow the capsule contents should be used (i.e., EFV should not be taken with a meal).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz (EFV)
Description: Participants will be administered oral EFV at a dose ranging from 50 mg to 800 mg once daily, based on weight and CYP 2B6 genotype. EFV capsules will be opened into a small amount of a compatible food or liquid vehicle; the smallest amount of food or liquid that will enable the child to swallow the capsule contents should be used (i.e., EFV should not be taken with a meal).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin-containing anti-TB therapy
Description: Treatment with rifampin-containing anti-TB treatment regimen. Treatment will last at least 24 weeks and up to 36 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin-containing anti-TB therapy
Description: Treatment with rifampin-containing anti-TB treatment regimen. Treatment will last at least 24 weeks and up to 36 weeks.
Study: NCT04638166

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mineral water
Description: Drinking mineral water for 12 weeks
Study: NCT05076162

Intervention type: DIAGNOSTIC_TEST
Intervention: PAED
Description: Delirium positive or negative

Intervention type: DIAGNOSTIC_TEST
Intervention: PAED
Description: Delirium positive or negative
Study: NCT04638166

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Plain water
Description: Drinking plain water for 12 weeks
Study: NCT02064595

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: External fixator
Description: Treatment with external fixation

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Intramedullary nail
Description: Fracture treated with intramedullary nail
Study: NCT01566318

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem-Solving Therapy
Description: 6-8 sessions over 8 weeks, with booster
Study: NCT00001849

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentetreotide
Description: Binds primarily to the somatostatin receptors subtypes (sst) 2 and 5. A high dose (18mCi) was used if the conventional dose (6mCi) was negative and scheduling was available. High doses limited to 3 over the course of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-DOPA
Description: 18F-DOPA is a radiolabeled amino acid used as a radiotracer in positron emission tomography (PET). Limited to 3 doses over the course of the study.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CT scan
Description: CT scan of chest, abdomen, neck and /or pelvis

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: MRI scan of head/pituitary, chest, abdomen, neck and /or pelvis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18-FDG
Description: FDG PET scan of body
Study: NCT01569451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: intravenous (IV) infusion of 1000 mg of rituximab on study days 1 (baseline visit) and 15

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glatiramer Acetate
Description: 20 mg injected subcutaneously daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glatiramer Acetate
Description: 20 mg injected subcutaneously daily

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Subjects will receive an intravenous (IV) infusion of 1000 mg of rituximab or placebo (normal saline) on study days 1 (baseline visit) and 15 according to the rituximab infusion protocol. On study day 28, all subjects will initiate standard GA therapy, 20 mg injected subcutaneously daily.
Study: NCT00543478

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saccharomyces boulardii
Description: 250mg, twice a day in sachets, for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methyl cellulose powder (low viscosity)
Description: twice a day sachets for 10 weeks
Study: NCT00118105

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Preoperative: 7.5 mg/kg, IV, Day 1 of cycles 1,2,3 Postoperative: 7.5 mg/kg, IV, Day 1 of cycles 1,2,3,4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Pre \& Post Operative: 1,700 mg/m\^2/day, PO at 12 hr interval, Days 1-14 of cycles 1,2,3,4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: 130 mg/m\^2, IV, Day 1 of cycles 1,2,3,4

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Description: Resection